YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer

Astellas

Status and phase: Terminated; Phase 2

Conditions: Prostate Cancer

Treatments: Drug: YM598

Study type: Interventional

Funder types: Industry

Identifiers

NCT00050297

598-CL-004

Details and patient eligibility

About

The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer.

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind